Clinical trials: Acute Exacerbation Chronic Pulmonary Disease
- Condition Acute Exacerbation Chronic Pulmonary Disease
- Funder type Industry (pharma, biotech, devices)
Chronic Bronchitis
Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis
A study to assess the safety and efficacy of moxifloxacin compared to that of amoxicillin-clavulanic acid for the treatment of subjects with acute exacerbation of chronic bronchitis.
- Trial name
- NCT00656747
- Testing
- Avelox (Moxifloxacin, BAY12-8039), Amoxicillin clavulanic acid
- Where
- 220 sites in Andorra, Argentina and 29 more
- Volunteers
- 1,372 people
- Sponsor
- Bayer
Bronchitis, Chronic
AVANTI - Avelox® in Acute Exacerbations of chroNic bronchiTIs
The objective of this global non-interventional study is to evaluate the impact of Acute Exacerbation of Chronic Bronchitis(AECB) on the patient and the community as well as the safety and effect of a treatment with Moxifloxacin…
- Trial name
- NCT00846911
- Testing
- Moxifloxacin (Avelox, BAY12-8039)
- Where
- 8 sites in Albania, Bosnia and Herzegovina and 6 more
- Volunteers
- 2,672 people
- Sponsor
- Bayer
Chronic Bronchitis, Disease Exacerbation
VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis
This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from an acute exacerbation of chronic bronchitis and take at least one dose of…
- Trial name
- VICTOR (NCT00876577)
- Testing
- Moxifloxacin (Avelox, BAY12-8039)
- Where
- China
- Volunteers
- 1,206 people
- Sponsor
- Bayer
Acute Bronchitis, Acute Exacerbations of Chronic Bronchitis
A Multicenter, Randomized, Double-blind, Parallel Group Study to Determine the Optimal Dose of HL301 After 7 Days Oral Administration in Acute Bronchitis or Acute Exacerbations of Chronic Bronchitis Patients (HL301: Mixed Extract of Rehmannia Glutinosa, Schisandra and so on)
The purpose of this study is to determine the optimal dose of HL301 in patients with acute bronchitis or acute exacerbations of chronic bronchitis.
- Trial name
- HL301 (NCT02250027)
- Testing
- HL301 300mg capsule
- Where
- South Korea
- Volunteers
- 156 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Bronchitis, Chronic
A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Cefuroxime Axetil in the Treatment of Adults With Persistent Bronchitis Experiencing Rapid Onset of Severe Worsening of Symptoms Caused by Bacteria
The purpose of this study is to evaluate the safety and effectiveness of levofloxacin, an antibiotic, compared with cefuroxime axetil, another antibiotic, in the treatment of adults with chronic bronchitis experiencing rapid…
- Trial name
- NCT00269932
- Testing
- levofloxacin
- Volunteers
- 485 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Bronchitis
A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis
Identifying the role of antibiotics in the treatment of subjects with a microbiologically documented acute exacerbation of chronic bronchitis (AECB) is the purpose of this clinical trial.
- Trial name
- NCT00255983
- Testing
- Faropenem medoxomil
- Where
- United States
- Volunteers
- 491 people
- Sponsor
- Replidyne
Chronic Obstructive Pulmonary Disease
Effect of Remote Physiologic Monitoring (RPM) on Outcomes in COPD Patients
This pre/post study was a retrospective analysis of unplanned hospitalization rates in a cohort of COPD subjects started on remote physiologic monitoring (RPM) at a large, outpatient pulmonary practice.
- Trial name
- NCT05518981
- Testing
- Respiratory Remote Patient Monitor (Spire Health Tag)
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Spire, Inc.
Lung Diseases, Bronchitis, Chronic
Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis
Moxifloxacin, is being tested at approximately 60 study centres in 15 countries to determine if this drug, when taken periodically in addition to the patients normal treatment, is effective at reducing the number of flare-ups of…
- Trial name
- NCT00473460
- Testing
- Avelox (Moxifloxacin, BAY12-8039)
- Where
- 78 sites in United States, Andorra and 13 more
- Volunteers
- 1,404 people
- Sponsor
- Bayer
Tracheitis, Tracheobronchitis
Evaluation of the Treatment With Klacid®SR in Patients With Lower Respiratory Tract Infection
The aim of this post-marketing observational study (PMOS) is to describe the relief of symptoms, tolerability and compliance of treatment with Klacid®SR in a dose 1000 mg once daily in patients with lower respiratory tract…
- Conditions
- Tracheitis, Tracheobronchitis, Bronchitis, Chronic Bronchitis
- Trial name
- NCT01108185
- Where
- 158 sites in Slovakia
- Volunteers
- 3,181 people
- Sponsor
- Abbott
Chronic Bronchitis
SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)
In this study data of patients with moderate or severe acute exacerbations of chronic bronchitis (AECB) were collected. There were two different cohorts which were compared (Moxifloxacin and other antibiotics) concerning…
- Trial name
- SYMPROVE III (NCT00879008)
- Testing
- Moxifloxacin (Avelox, BAY12-8039)
- Where
- Germany
- Volunteers
- 345 people
- Sponsor
- Bayer
Chronic Bronchitis
PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis
Primary Objective: The primary objective of the study is to demonstrate the superiority of telithromycin over azithromycin and over cefuroxime axetil in the reduction of Streptococcus pneumoniae (Sp) strains resistant to…
- Trial name
- NCT00132938
- Testing
- telithromycin
- Where
- 8 sites in United States, Belgium and 6 more
- Volunteers
- 5,660 people
- Sponsor
- Sanofi
Bronchitis, Chronic
Telithromycin in Acute Exacerbation of Chronic Bronchitis
Study objectives: to document the clinical efficacy of telithromycin(800 mg per day for 5 days) at Test Of the Cure (TOC)visit (D12-D19), in acute exacerbation of chronic bronchitis.
- Trial name
- NCT00288223
- Testing
- Telithromycin
- Where
- Turkey (Türkiye)
- Volunteers
- 54 people
- Sponsor
- Sanofi
Chronic Obstructive Pulmonary Disease
A Study of the Inflammatory Pathways Associated With Chronic Obstructive Pulmonary Disease Exacerbations
The purpose of this study is to observe how the inflammatory pathways differ in subjects with chronic obstructive pulmonary disease (COPD) during an acute exacerbation of COPD (AECOPD).
- Trial name
- NCT01337661
- Where
- Ireland
- Volunteers
- 26 people
- Sponsor
- MedImmune LLC
Chronic Obstructive Pulmonary Disease COPD
A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy
The purpose of this study is to determine whether AZD7624 can reduce acute Chronic Obstructive Pulmonary Disease (COPD) exacerbations in patients on COPD maintenance therapy with a history of frequent acute exacerbations.
- Trial name
- NCT02238483
- Testing
- AZD7624 1.0 mg
- Where
- 41 sites in United States, Argentina and 4 more
- Volunteers
- 213 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients
Patients with Chronic Obstructive Pulmonary Disease (COPD) suffer from frequent and recurrent acute exacerbations (AECB) which are associated with enormous healthcare expenditures and significant morbidity, specifically an…
- Trial name
- NCT00739648
- Testing
- MP-376
- Where
- 39 sites in United States
- Volunteers
- 322 people
- Sponsor
- Amgen
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Clinical Practice of AECOPD Management in China
The purpose of this study is observe clinical practice including glucocorticoids treatment in AECOPD in China.
- Trial name
- NCT02051166
- Where
- 13 sites in China
- Volunteers
- 5,095 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Clinical Evaluation of SenseGuard™ to Detect Respiratory Changes, During Home Monitoring of Subjects With High Risk of AECOPD.
This is an observational, open labeled study. The study aims to evaluate the capability of SenseGuard™ (SG) non-invasive wearable device, to detect, post-hoc, early respiratory changes due to exacerbation by daily monitoring of…
- Trial name
- NCT05119374
- Testing
- SenseGuard Investigational Device
- Where
- 6 sites in Israel
- Volunteers
- 57 people
- Sponsor
- NanoVation
COPD Exacerbation Acute
A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease, that causes obstructed airflow from the lungs that causes persistent obstructive airflow limitation.
- Trial name
- NCT05400369
- Testing
- Sitafloxacin, Moxifloxacin Hydrochloride
- Where
- 18 sites in China
- Volunteers
- 140 people
- Sponsor
- Daiichi Sankyo
COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbation
A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate chronic obstructive pulmonary disease (COPD)
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbation, COPD Exacerbation Acute
- Trial name
- R-3750-01-LU (NCT07076290)
- Testing
- R-3750
- Volunteers
- 27 people
- Sponsor
- Rise Therapeutics LLC
Pulmonary Disease, Chronic Obstructive, Infections, Bacterial
Observational Study Of An Electronic Questionnaire In Patients With Chronic Obstructive Pulmonary Disease (COPD)
The aim of the study is to develop a new patient-reported outcome (PRO) questionnaire measuring the impact of an acute exacerbation on daily lives of patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00259909
- Testing
- GSK questionnaire, St. George's Respiratory Questionnaire, Acute Short Form 12 version 2
- Where
- 123 sites in United States, Germany and 1 more
- Volunteers
- 259 people
- Sponsor
- GlaxoSmithKline